With First US Approval, BeiGene’s Tevimbra To Start Small, Work Its Way Up

The FDA approved the PD-1 inhibitor for previously treated esophageal cancer, while BeiGene anticipates decisions on first-line ESCC as well as G/GEJ cancer later in the year.